People

Hans Schreiber, MD PhD

The main focus of this laboratory is to study the fundamental mechanisms that govern the interaction of cancer cells with the immune system. In particular, our laboratory is trying to exploit the fact that cancer cells usually carry cancer-specific mutations and antigens, and that under certain conditions, the immune system can destroy cancer cells even after they have disseminated in the body. We are trying to understand the mechanisms that often allow immunogenic cancer cells to escape immune destruction, and we want to develop new strategies and principles on which to base novel therapeutic approaches. We are also studying the signals needed for the immune system to be alerted be cancer cells, and then to destroy these cells. Finally, we combine immunology with genetics and biochemistry, which provides us with a powerful tool to search for cancer-specific changes in malignant cells in order to identify critical mechanisms and immunological targets that can be used to destroy the cancer.

The University of Chicago
Chicago
Ph.D
1977

Charite University Medicine
Berlin, Germany
Internship
1974

State of Baden-Wuerttemberg
Germany
Medical License
1974

Oak Ridge National Laboratory/Atomic Energy Comission, Biology Division
Post Doctoral - Experimental Carcinogenesis, Microbiology, and Cytology
1973

Educational Council for Foreign Medical Graduates
Diploma
1973

University of Freiburg
Germany
MD
1969

University of Freiburg
Germany
D.M.Sc. - Experimental Pathology, Radiation Biology
1969

Pritzer School of Medicine
Residency - Anatomic Pathology

Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents.
Hu Y, Cao G, Chen X, Huang X, Asby N, Ankenbruck N, Rahman A, Thusu A, He Y, Riedell PA, Bishop MR, Schreiber H, Kline JP, Huang J. Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents. Matter. 2021 Dec 01; 4(12):3917-3940.
PMID: 34901832

Criteria to make animal studies more relevant to treating human cancer.
Wolf SP, Wen FT, Schreiber H. Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2022 Feb; 74:25-31.
PMID: 34619458

Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens.
Böttinger P, Schreiber K, Hyjek E, Krausz T, Spiotto MT, Steiner M, Idel C, Booras H, Beck-Engeser G, Riederer J, Willimsky G, Wolf SP, Karrison T, Jensen E, Weichselbaum RR, Nakamura Y, Yew PY, Lambert PF, Kurita T, Kiyotani K, Leisegang M, Schreiber H. Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis. 2020 11 13; 41(11):1605-1615.
PMID: 32221533

Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.
Sharma P, Marada VVVR, Cai Q, Kizerwetter M, He Y, Wolf SP, Schreiber K, Clausen H, Schreiber H, Kranz DM. Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proc Natl Acad Sci U S A. 2020 06 30; 117(26):15148-15159.
PMID: 32541028

LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor ß Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
Xu W, Yang Y, Hu Z, Head M, Mangold KA, Sullivan M, Wang E, Saha P, Gulukota K, Helseth DL, Guise T, Prabhkar BS, Kaul K, Schreiber H, Seth P. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor ß Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models. Hum Gene Ther. 2020 08; 31(15-16):863-880.
PMID: 32394753

Automated cell cluster analysis provides insight into multi-cell-type interactions between immune cells and their targets.
Diehl MI, Wolf SP, Bindokas VP, Schreiber H. Automated cell cluster analysis provides insight into multi-cell-type interactions between immune cells and their targets. Exp Cell Res. 2020 08 15; 393(2):112014.
PMID: 32439494

Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors.
Schreiber K, Karrison TG, Wolf SP, Kiyotani K, Steiner M, Littmann ER, Pamer EG, Kammertoens T, Schreiber H, Leisegang M. Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. Cancer Immunol Res. 2020 02; 8(2):192-202.
PMID: 31831634

Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell.
He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, Schreiber H. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019 Dec 05; 4(23).
PMID: 31801912

Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell.
He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, Schreiber H. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019 11 01; 4(21).
PMID: 31672936

Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
Friedman J, Moore EC, Zolkind P, Robbins Y, Clavijo PE, Sun L, Greene S, Morisada MV, Mydlarz WK, Schmitt N, Hodge JW, Schreiber H, Van Waes C, Uppaluri R, Allen C. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Clin Cancer Res. 2020 02 01; 26(3):679-689.
PMID: 31645352

View All Publications